Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 7, 2026
Early symptom response in patients with uncomplicated urinary tract infection treated with gepotidacin or nitrofurantoin: pooled analysis from two pivotal Phase 3 studies
Amanda J Sheets, Jeremy Dennison, Jason M Pogue, et al.
British Journal of Clinical Pharmacology
|
July 21, 2021
Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague
Dung Nguyen, Jafar Sadik Shaik, Guoying Tai, et al.
Molecular Metabolism
|
August 8, 2022
Nicotinamide riboside alleviates exercise intolerance in ANT1-deficient mice
Patrick M Schaefer, Jessica Huang, Arrienne Butic, et al.
Contemporary Clinical Trials Communications
|
December 16, 2025
Impact of updated regulatory guidelines on study results in contemporary uncomplicated urinary tract infection clinical trials and implications for trial conduct and drug development: a comparative analysis with EAGLE-2 and EAGLE-3
Florian Wagenlehner, Keith S Kaye, David A Talan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 7, 2026
Subgroup Analysis of Pooled Phase 3 Efficacy Data from Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) including Participants with Uropathogens Not-Susceptible to Nitrofurantoin
Amanda Sheets, Jeremy Dennison, Jennifer H Han, et al.
Metabolomics : Official Journal of the Metabolomic Society
|
May 6, 2020
Tissue metabolic profiling shows that saccharopine accumulates during renal ischemic-reperfusion injury, while kynurenine and itaconate accumulate in renal allograft rejection
Ulf H Beier, Erum A Hartung, Seth Concors, et al.
Lancet (London, England)
|
April 17, 2025
Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study
Jonathan D C Ross, Janet Wilson, Kimberly A Workowski, et al.
Nature
|
September 9, 2020
SLC25A51 is a mammalian mitochondrial NAD<sup>+</sup> transporter
Timothy S Luongo, Jared M Eller, Mu-Jie Lu, et al.
British Journal of Cancer
|
January 17, 2020
MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer
Jessica C Casciano, Caroline Perry, Adam J Cohen-Nowak, et al.
Cell Reports
|
December 16, 2020
Lactate Limits T Cell Proliferation via the NAD(H) Redox State
William J Quinn, Jing Jiao, Tara TeSlaa, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 7, 2026
Early symptom response in patients with uncomplicated urinary tract infection treated with gepotidacin or nitrofurantoin: pooled analysis from two pivotal Phase 3 studies
Amanda J Sheets, Jeremy Dennison, Jason M Pogue, et al.
British Journal of Clinical Pharmacology
|
July 21, 2021
Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague
Dung Nguyen, Jafar Sadik Shaik, Guoying Tai, et al.
Molecular Metabolism
|
August 8, 2022
Nicotinamide riboside alleviates exercise intolerance in ANT1-deficient mice
Patrick M Schaefer, Jessica Huang, Arrienne Butic, et al.
Contemporary Clinical Trials Communications
|
December 16, 2025
Impact of updated regulatory guidelines on study results in contemporary uncomplicated urinary tract infection clinical trials and implications for trial conduct and drug development: a comparative analysis with EAGLE-2 and EAGLE-3
Florian Wagenlehner, Keith S Kaye, David A Talan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 7, 2026
Subgroup Analysis of Pooled Phase 3 Efficacy Data from Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) including Participants with Uropathogens Not-Susceptible to Nitrofurantoin
Amanda Sheets, Jeremy Dennison, Jennifer H Han, et al.
Metabolomics : Official Journal of the Metabolomic Society
|
May 6, 2020
Tissue metabolic profiling shows that saccharopine accumulates during renal ischemic-reperfusion injury, while kynurenine and itaconate accumulate in renal allograft rejection
Ulf H Beier, Erum A Hartung, Seth Concors, et al.
Lancet (London, England)
|
April 17, 2025
Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study
Jonathan D C Ross, Janet Wilson, Kimberly A Workowski, et al.
Nature
|
September 9, 2020
SLC25A51 is a mammalian mitochondrial NAD<sup>+</sup> transporter
Timothy S Luongo, Jared M Eller, Mu-Jie Lu, et al.
British Journal of Cancer
|
January 17, 2020
MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer
Jessica C Casciano, Caroline Perry, Adam J Cohen-Nowak, et al.
Cell Reports
|
December 16, 2020
Lactate Limits T Cell Proliferation via the NAD(H) Redox State
William J Quinn, Jing Jiao, Tara TeSlaa, et al.
Page
of 4